Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma

International Journal of Clinical Oncology

Volumn 18, Issue 5, 2013, Pages 877-883

  Yasuda, Yosuke ^a   Fujii, Yasuhisa ^a   Yuasa, Takeshi ^a   Kitsukawa, Shinichi ^a   Urakami, Shinji ^a   Yamamoto, Shinya ^a   Yonese, Junji ^a   Takahashi, Shunji ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bone metastases; Renal cell carcinoma; Survival; Zoledronic acid

Indexed keywords

CALCIUM; SORAFENIB; SUNITINIB; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; BONE NEOPLASMS; CALCIUM; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84886093644     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0472-y     Document Type: Article

References (35)

1. Dekernion JB, Ramming KP, Smith RB et al (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:148-152
2. Skinner DG, Colvin RB, Vermillion CD et al (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 28:1165-1177
3. Montie JE, Stewart BH, Straffon RA et al (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 117:272-275
4. Thompson IM, Shannon H, Ross G Jr et al (1975) An analysis of factors affecting survival in 150 patients with renal carcinoma. J Urol. 114:694-696
5. Coleman RE (2000) Management of bone metastases. Oncologist 5:463-470
6. Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295-306
7. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
8. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314
9. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
10. Lipton A, Zheng M, Seaman J et al (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962-969
11. Kijima T, Fujii Y, Suyama T et al (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620-624
12. Yuasa T, Urakami S, Yamamoto S et al (2011) Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 28:405-411
13. Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794-1801
14. Althausen P, Althausen A, Jennings LC et al (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80:1103-1109
15. Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223-231
16. Kume H, Kakutani S, Yamada Y et al (2011) Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol 185:1611-1614
17. Szendroi A, Dinya E, Kardos M et al (2010) Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res 16:29-38
18. Toyoda Y, Shinohara N, Harabayashi T et al (2007) Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 52:163-168
19. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
20. Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145-1153
21. Guise TA (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34:19-24
22. Ullen A, Schwarz S, Lennartsson L et al (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43:98-103
23. Yuasa T, Sato K, Ashihara E et al (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58:493-502
24. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
25. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
26. Zołnierek J, Nurzyński P, Langiewicz P et al (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371-378
27. Sundaresan N, Galicich JH, Lane JM et al (1985) Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization. J Neurosurg 63:676-684
28. Maranzano E, Latini P (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32:959-967
29. Leviov M, Dale J, Stein M et al (1993) The management of metastatic spinal cord compression: a radiotherapeutic success ceiling. Int J Radiat Oncol Biol Phys 27:231-234
30. Zelefsky MJ, Scher HI, Krol G et al (1992) Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer 70:2319-2325
31. Newman EM, Bouvet M, Borgehi S et al (2006) Causes of hypercalcemia in a population of military veterans in the United States. Endocr Prac 12:535-541
32. Lee C, Yang C, Lam K et al (2006) Hypercalcemia in the emergency department. Am J Med Sci 331:119-123
33. Vassilopoulou-Sellin R, Newman B, Taylor S et al (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:1309-1312
34. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865-875
35. Shinohara N, Abe T, Mochizuki T et al (2011) Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol (in press)